Psychiatry and Neurology, Neurology · San Francisco, CA
NPI
1477599454
Since 2006
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
3
Medicare group memberships
Hospitals
2
Hospital affiliations
1500 Owens St Ste 320
San Francisco, CA, 94158
Phone (415) 353-2069
Groups this clinician bills Medicare through
Medicare paid, 2024
$200K
2,034 services
Medicare patients, 2024
109
Average age 65
Drug cost, 2024
$1.6M
680 prescriptions
Company payments, 2025
$58K
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Bruce A Cree was code 99215 (office e&m - established), 116 times for 84 patients. In total Bruce A Cree billed 2,034 services in 20 codes, and Medicare paid $200K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-01-30.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 116 | 84 | $119.28 | $14K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 114 | 87 | $14.01 | $1,597 |
| 99214 Office E&M - Established | Office | 33 | 31 | $65.84 | $2,173 |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 30 | 19 | $24.06 | $722 |
By year: 2022 $17K for 165 services; 2023 $17K for 224 services; 2024 $200K for 2,034 services.
Medicare prescription drug claims, 2024
In 2024, the drug Bruce A Cree prescribed most often to Medicare patients was Gabapentin, with 85 prescriptions and refills. In total Bruce A Cree wrote 680 Medicare prescriptions that cost $1.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Gabapentin Generic | 85 | 199 | 24 | $2,848 |
| Dalfampridine Er Dalfampridine | 62 | 132 | 14 | $37K |
| Baclofen Generic | 54 | 140 | 17 | $3,363 |
| Kesimpta Pen Ofatumumab | 41 | 73 | Under 11 | $592K |
| Myrbetriq Mirabegron | 36 | 63 | Under 11 | $29K |
| Modafinil Generic | 25 | 33 | Under 11 | $2,328 |
| Oxybutynin Chloride Er Oxybutynin Chloride | 24 | 70 | Under 11 | $1,140 |
| Mayzent Siponimod | 22 | 50 | Under 11 | $447K |
| Escitalopram Oxalate Generic | 16 | 41 | Under 11 | $159 |
| Metformin Hcl Er Metformin Hcl | 16 | 26 | Under 11 | $85.24 |
| Dimethyl Fumarate Generic | 15 | 19 | Under 11 | $3,152 |
| Rizatriptan Rizatriptan Benzoate | 13 | 13 | Under 11 | $248 |
| Diazepam Generic | 13 | 17 | Under 11 | $92.14 |
| Tecfidera Dimethyl Fumarate | 12 | 12 | Under 11 | $60K |
| Clemastine Fumarate Generic | 12 | 23 | Under 11 | $2,032 |
Brand drugs: 136 claims; generic drugs: 544 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Bruce A Cree $58K ($47K in general payments such as food, travel and fees and $10K for research) from 10 companies. The largest payer was Genzyme Corporation with $42K.
| Company | Payments | Amount |
|---|---|---|
| Genzyme Corporation SNY | 15 | $42K |
| TG Therapeutics, Inc. TGTX | 16 | $9,534 |
| Biogen, Inc. BIIB | 4 | $4,298 |
| Novartis Pharma AG NVS | 2 | $1,276 |
| F. Hoffmann-La Roche AG ROG.SW | 1 | $306 |
| Amgen Inc. AMGN | 3 | $260 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $82.39 |
| Alexion Pharmaceuticals, Inc. AZN | 1 | $56.37 |
| Genentech USA, Inc. ROG.SW | 1 | $32.01 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.